QuanBio.com

Compensation

Full Description

Company Description QuanBio develops clinical intelligence rooted in human vascular physiology to provide a more complete view of cardiovascular health and disease progression. By capturing dynamic vascular function, the company enables earlier detection of pathology, precise disease characterization, and insight into treatment response over time. Our platform integrates vascular intelligence, digital biomarkers, ICU hemodynamic intelligence, and deployable screening infrastructure to support cardiovascular drug discovery, trial enrichment, and post-market real-world evidence generation. With funded clinical programs active domestically and internationally, QuanBio is entering a focused commercial scale phase. Role Mandate QuanBio is expanding pharmaceutical engagement in cardiovascular and related therapeutic areas and is seeking a senior strategic commercial partner to support enterprise-level collaboration. This mandate includes: • Structuring and advancing platform-level pharmaceutical partnerships • Introducing QuanBio’s cardiovascular data and screening capabilities to senior decision-makers in drug development and translational medicine • Positioning real-world evidence and vascular intelligence solutions within discovery, clinical development, and lifecycle strategy • Driving executive-level strategic relationships across global pharmaceutical organizations QuanBio is clinically validated, institutionally partnered, and actively scaling. This is not an accelerator-stage opportunity. Ideal Profile • Established executive-level relationships within global pharmaceutical cardiovascular franchises • Experience structuring enterprise data, analytics, or platform agreements • Deep understanding of biomarker-driven development and clinical trial strategy • Senior presence capable of engaging at therapeutic area and C-suite leadership levels • Entrepreneurial mindset and comfort operating in a performance-based structure We welcome select senior-level individuals or specialized life sciences commercial firms with demonstrated cardiovascular pharma success. This is a remote, performance-aligned commercial mandate. While location is flexible, presence in the Northeast corridor is advantageous. Compensation is structured around performance-based upside and long-term platform alignment.